Objectives: To evaluate the effectiveness of low-dose oral erythromycin to treat feeding intolerance in preterm infants.
Premature infants frequently suffer from feeding intolerance and are subsequently exposed to nasoduodenal feeding and parenteral nutrition (PN) for prolonged times. 1 Procedural pain associated with prolonged intravenous hyperalimentation seems a minor issue when performed with proper anesthesia and analgesia. However, these infants can present with serious and even life-threatening complications that include liver dysfunction and bloodstream infections. 1 Establishing enteral feeding is therefore a critical milestone during management of premature infants. As feeding intolerance in premature infants is mainly functional, prokinetic drugs have been used with increasing frequency in newborn infants. The repertoire of available prokinetic agents is unfortunately rather limited and efficacy and safety data involving pediatric patients are sparse. 2, 3 Erythromycin, one of the macrolide group of antibiotics, is a motilin agonist with a prokinetic effect. It has been used in the treatment of gastrointestinal dysmotility in adults and children. [4] [5] [6] Evidence for its use in neonates is conflicting. 7 The objective of this prospective, double-blinded, placebo-controlled randomized trial was to evaluate the effectiveness of erythromycin as a prokinetic drug in promoting gastrointestinal motility in preterm infants with feeding intolerance.
Subjects and methods

Eligibility
The study was approved by the Institutional Review Board at Mansoura University Children's Hospital in Egypt. The trial was conducted at the neonatal intensive care unit (NICU) of Mansoura University Children's Hospital. Infants were eligible for the trial when they met the following criteria: (i) gestational age less than 37 weeks determined by a combination of maternal dates, early antenatal ultrasound and Ballard score, 8 (ii) had feeding intolerance defined as repeated pre-feed gastric residuals >30% of the previous 6 h feed, (iii) were fed cow's protein-based formula and (iv) had informed parental consent to enroll in the study. Infants were excluded from the study if they had major congenital malformations, anatomical gastrointestinal anomalies, birth asphyxia; the presence or history of necrotizing enterocolitis (NEC), confirmed sepsis and organic abdominal illness.
Study design
The study was designed as a prospective double-blinded placebo-controlled randomized trial. After enrollment, each infant was randomly assigned either erythromycin or placebo using parallel blocks of 10 according to a predetermined list of random numbers. Randomization was also stratified on enrollment into gestational age groups of p32 and >32 weeks. According to a predetermined list of random numbers, babies were allocated to either erythromycin or placebo. Randomization was carried out by cards provided in consecutively numbered, opaque, sealed envelopes. A separate set of cards was prepared for each gestational age stratum.
Sample size
Baseline rate of attaining full enteral feedings was derived from review of non-erythromycin-treated infants in the 12 months before this study was started. We hypothesized that erythromycin would reduce the length of time to achieve full feed by 40%. A sample size of 48 subjects (24 in each group) was required to test our hypothesis with a power of 0.80 and a significant P-value of <0.05.
Study end points
The primary end point was the duration required by the infant to achieve full enteral feeds. Full enteral feed was satisfied when the infant tolerated a volume of 150 ml/kg/day for at least 24 h. Other end points included number of episodes of gastric residuals >30% of the previous 6 h feeds, weight gain after enrollment in the trial (g/day), duration of PN, duration of hospital stay and occurrence of NEC. The study medicine (erythromycin or placebo) was to stop once the primary end point is achieved.
Feeding protocols
Feeds were begun in both groups of infants when they were clinically stable and were given as intermittent boluses every 3 h through a nasogastric tube. All infants received cow's protein-based milk formula for premature infants (S26, Wyeth Nutritionals, Ireland) used in a standard dilution (80 kcal/100 ml). The initial feeding volume was 10 ml/kg/day and the volume was increased by 20 ml/kg/day daily if tolerated until complete enteral feed was achieved. Infants were kept prone, with the head of the cot raised, and minimally handled for 1 h after the feeds.
Gastric residuals were measured every 6 h before the feed. A gastric residual of greater than 30% of the previous 6-h feed volume was regarded as significantly large and further increments were withheld. Feeds were withheld if vomiting occurred more than once in 24 h, the volume of gastric residuals exceeded half of the oral intake in the previous 6 h; clinical signs and symptoms suggestive of NEC or other ominous intra-abdominal pathologies; or repeated regurgitation and aspiration pneumonia were suspected. The feeding policy was uniform in all babies.
Therapy/Placebo
Those in the 'erythromycin' group received the drug at a dose of 1 mg/kg every 8 h. We used erythromycin ethylsuccinate oral suspension (Erythrocin, Abbott Laboratories, Abbott Park, IL, USA), diluted to 4 mg/ml with sterile water. Those assigned to receive placebo solution were given an equivalent volume of normal saline. As the oral erythromycin preparation is white liquid suspension, both active drug and normal saline were mixed thoroughly into the milk feeds to mask their appearance from attending clinical team. This procedure was performed by designated staff not involved in the clinical management of these infants. Neonatal management was the same in the two groups, except for erythromycin administration. Standard care of infants in the NICU did not change appreciably over the observation period.
Statistical analysis
Comparisons for continuous variables were made by two-tailed independent samples Student's t-test for normally distributed data and by Mann-Whitney rank sum test for non-normally distributed data. For comparisons of categorical data, w 2 test and Fisher's exact test were used wherever applicable. The computer program SPSS; Release 10.0 (SPSS Inc., Chicago, IL, USA) was used for statistical evaluation and the level of significance was set at P<0.05 and all P-values reported in this trial are of the two-sided type.
Results
A total of 60 subjects were enrolled and randomly assigned to either erythromycin (n ¼ 30) or placebo (n ¼ 30) groups. Randomization was carried out in two gestational age strata (p32 and >32 weeks). Five infants in the 'erythromycin' group and six infants in the 'placebo' group died before achieving full enteral feeding. Therefore, 49 infants completed the study and satisfied the primary end point of achieving full enteral feed. The erythromycin group included 25 infants (13 infants p32 weeks and 12 infants >32 weeks) and the placebo group included 24 infants (12 infants p32 weeks and 12 infants >32 weeks). There were no statistically significant differences between both groups regarding demographic data and clinical characteristics (Table 1) . Duration to achieve full enteral feeding The use of erythromycin was associated with an earlier achievement of full enteral feedings in infants with gestational age >32 weeks (10.5±4.1 vs 16.3±5.7 days, P ¼ 0.01), but did not demonstrate any difference in infants p32 weeks (18.7±8.1 vs 20.7±6.1, P>0.05). In addition, erythromycin was associated with fewer episodes of gastric residuals in infants >32 weeks (P<0.05), but not in infants p32 weeks.
Duration of PN, hospital stay and weight gain
In infants with gestational age >32 weeks, the 'erythromycin' group had shorter duration of PN compared to those in the 'placebo' group (5.5±3.3 vs 9.4±4.8, P<0.05). There were no significant differences between groups regarding the duration of hospital stay and weight gain. In infants with gestational age p32 weeks, there were no significant differences between 'erythromycin' and 'placebo' groups regarding the duration of PN (12.6±6.3 vs 12.6±5.4, P>0.05), duration of hospital stay and weight gain ( Table 2 ).
Adverse outcomes
There were no significant differences between 'erythromycin' (n ¼ 30) and 'placebo' (n ¼ 30) groups in the incidence of mortality, sepsis, NEC and cholestatic jaundice ( Table 3 ). The treatment was not associated with any noticeable complications. When the study end point was achieved, the discontinuation of the study medicine was not associated with any rebound or intolerance to feed. (Table 3) .
Discussion
Premature infants older than 32 weeks gestation who enterally received low-dose erythromycin achieved full enteral feedings 5.8 days sooner. In addition, they had fewer episodes of gastric residuals and required shorter duration of PN. On the other hand, erythromycin did not demonstrate any advantage in premature infants p32 weeks gestation. Erythromycin was previously shown to be effective in shortening the length of time required to achieve full enteral feeding. The efficacy of erythromycin was noticeable in previous studies even in the earliest gestational age when it was given enterally at a higher dose (30 mg/kg/day), or when a low dose (3 mg/kg/day) was administered intravenously. 9, 10 Our study offers a potentially simpler approach by using the smaller dose of erythromycin (3 mg/kg/day), while still administered enterally. It appears from our study that a low enteral dose is quite beneficial in decreasing feeding intolerance in premature infants older than 32 weeks gestation. However, such a low dose seems insufficient to treat preterm infants with gestational age p32 weeks.
The decrease in the incidence and frequency of large gastric residuals in premature infants >32 weeks in our study suggests that erythromycin enhances gastric emptying and thereby reduces gastric stasis. These findings correlate with previous observations of erythromycin that markedly decrease gastric residuals in infants with feeding intolerance. 3, 10 There is substantial evidence to support the suggestion that erythromycin exerts its gastrointestinal motor effects through activation of the neural motilin receptors on cholinergic neurons and the smooth muscle motilin receptors of the upper gastrointestinal tract. 11 Stimulation of the motilin pathway results in greater amplitude and more frequent antral 14 and suppression of pyloric pressure waves, which is associated with reduced pyloric outlet resistance and an increase in duodenal contraction frequency. 15 Combination of the aforementioned mechanisms is thus likely to produce powerful propulsive forces which effectively propel the gastric luminal contents distally towards the small and large bowels and improve gastrointestinal motility. Of note, all infants in this study were maintained in prone position for an entire hour following each feed. Similar effectiveness for erythromycin cannot be extrapolated, had these infants been kept in supine position or on their sides. Despite a significant improvement in tolerance to feed, erythromycin was not associated with a shorter duration of hospital stay. This can be explained by the fact that hospital stay depends on several factors that cannot be modified by the use of erythromycin. Examples of these factors are oral readiness, the presence of apnea and education and preparedness of family.
Low doses of oral erythromycin did not ameliorate the course of feeding intolerance in premature infants p32 weeks of our study. In a recent study, 16 it was found that oral erythromycin failed to induce phase III of migrating motor complexes (MMCs) in infants younger than 31 weeks gestation; however, it induced phase III in a dose-dependent manner among infants whose gestational ages were 32 weeks and older. It seems that erythromycin, as a motilin agonist, is able to augment the appearance of MMCs in premature infants in a manner that is very dependent on their gestational maturity. 17, 18 In infants younger than 32 weeks of gestation, no MMCs were identified even though plasma concentrations of motilin were comparable to that of adults. 18 It is plausible that preterm infants >32 weeks gestation have anatomic and functional coupling capabilities such as the presence of motilin receptors, cholinergic neurons, myenteric plexus, interstitial cells of Cajal and enteric smooth muscle. Conversely, the more immature preterm infants lack the appropriately developed functional circuitry, required for erythromycin to induce phase III episodes. 16 In addition to gastric stasis several other immature host factors, on which erythromycin may have no effect, determine oral feed tolerance in preterm infants younger than 32 weeks. These may include immaturity of the digestive and absorptive capacity of the gut. Finally, it is important to clarify that the process of gut maturation in premature infants may vary from one infant to another. Therefore, one cannot determine a specific gestational age as a prerequisite for erythromycin efficacy. This concept explains the contradicting finding in different trials on the use of erythromycin in premature infants. 10, 19 In summary, low-dose oral erythromycin had beneficial effects on feeding intolerance and it shortened the duration of PN in preterm infants older than 32 weeks gestation. A similar effect was not found in younger preterm infants. Further studies are necessary to ensure the safety of its administration in preterm infants. Until then, erythromycin should be used cautiously in this population. Finally, this study was conducted on formula-fed premature infants and does not provide any data to suggest whether infants receiving breast milk would respond similarly to erythromycin or not. Values are expressed as number (%).
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